United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - infectious bovine rhinotraceitis virus - powder and solvent for solution for injection - live viral vaccine - cattle

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated mannheimia haemolytica strain x387; inactivated m. haemolytica leucotoxin strain x332 - misc. vaccines or anti sera - inactivated mannheimia haemolytica strain x387 vaccine - general active 0.0 p; inactivated m. haemolytica leucotoxin strain x332 vaccine - general active 0.0 p - immunotherapy

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - infectious bovine rhinotraceitis virus - powder and solvent for solution for injection - live viral vaccine - cattle

United Kingdom - English - VMD (Veterinary Medicines Directorate)

intervet international bv - infectious bovine rhinotraceitis virus - suspension for injection - inactivated viral vaccine - cattle

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - bohv type i, strain difivac, ge-deletion mutant inactivated - emulsion for injection - . - live and inactivated viral vaccines - cattle - immunological - inactivated vaccine

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 1440 elisa unit - injection, suspension - excipient ingredients: polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; aluminium hydroxide hydrate; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote aboriginal and torres strait islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. homosexual men : increased incidence of hepatitis a infection among homosexual males suggests that the disease may be sexually transmitted in this group. contacts of infected persons : since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. the use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. specific population groups known to have a higher incidence of hepatitis a: eg. australian aboriginals, recognised community-wide hav epidemics. individuals with chronic liver disease and recipients of liver transplants, as hepatitis a infections is likely to be more severe in these groups. many injecting drug users will have pre-existing liver disease from hepatitis b or hepatitis c infection. recipients of blood products, such as factor viii eg. haemophiliacs. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis d virus, hepatitis e or other pathogens known to infect the liver.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - infectious bovine rhinotraceitis virus - suspension for injection - inactivated viral vaccine - cattle

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - infectious bovine rhinotraceitis virus - suspension for injection - inactivated viral vaccine - cattle

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - infectious bovine rhinotraceitis virus - suspension for injection - inactivated viral vaccine - cattle

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - infectious bovine rhinotraceitis virus - suspension for injection - inactivated viral vaccine - cattle